You are here: All Products  > BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products